MAP2K7 and melanoma: Although, we did not identify any melanoma cell lines with PIK3CA activating mutations in the GDSC database, these data indicate that activating RAS mutations and loss-of-function NF1 or PTEN mutations do not diminish the sensitivity of melanoma cell lines to MEK inhibition in vitro.